Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...
Reexamination Certificate
2004-11-19
2008-11-25
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds bacterium or component thereof or substance produced...
C424S150100, C514S002600, C514S018700, C514S019300, C514S312000
Reexamination Certificate
active
07455840
ABSTRACT:
The present invention provides methods and compositions for said inhibition of drug resistance. In one embodiment, said invention provides methods and compositions for said inhibition of antibiotic resistance. The invention generally involves said administration of achaogens, agents that inhibit said mutational process, to inhibit said evolution of drug resistance. Also, described herein are compositions that are suitable for use as achaogens.
REFERENCES:
patent: 5945285 (1999-08-01), Mekalanos et al.
patent: 6054431 (2000-04-01), Horwitz et al.
patent: 6410514 (2002-06-01), Isaacs et al.
patent: 6503881 (2003-01-01), Krieger et al.
patent: 2002/0022718 (2002-02-01), Forsyth et al.
patent: 2002/0045592 (2002-04-01), Zyskind et al.
patent: 2004/0029129 (2004-02-01), Wang et al.
patent: 2004/0147006 (2004-07-01), Bullock
patent: 2004/0185530 (2004-09-01), Janjic et al.
patent: 2005/0108047 (2005-05-01), David
patent: 2002-114704 (2002-04-01), None
Baker, “Battling Evolution to Fight Antibiotic Resistance,” The Scientist, 2005, 19, 17 printed from http://www.the-scientist.com/2005/10/10/17/1, pp. 1-7.
Harbottle et al., “Genetics of antimicrobial resistance,” Anim. Biotechnol., 2006, 17, 11, abstract only.
Van Bambeke, “Quinolones in 2005: an update,” Clin. Microbiol. Infect., 2005, 11, 256-80.
Corkill et al., “High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK,” J. Antimicrob. Chemo., 2005, 56, 115-7.
Ginalski et al. “Practical lessons from protein structure prediction,” Nuc. Ac. Res., 2005, 33, 1874.
Cejka et al. “Short interfering RNA: tool or therapeutic?” Clin. Sci., 2006, 110, 47-58.
Sutter et al. “Gene therapy for gastric cancer: is it promising?” World J Gastroenterol., 2006, 12, 380-7.
Miyakawa et al. In Vitro Activity of the Antimicrobial Peptides . . . Infection And Immunity. Mar. 1996, vol. 64, No. 3, pp. 926-932.
Yasuda et al. Inhibition ofEschericia coliRecA coprotease activities by Dinl. The EMBO Journal. 1998, vol. 17, No. 11, pp. 3207-3216.
Naslund et al. Inhibition of recA induction by the radioprotector 2-mercaptoethylamine. Mutation Research. 1992, vol. 282, pp. 203-207.
Piddock et al. Correlation of Quinolone MIC and Inhibition of DNA . . . Antimicrobial Agents And Chemotherapy. Dec. 1990, vol. 34, No. 12, pp. 2331-2336.
Miller et al. (2004) “SOS Response Induction by β-Lactams and Bacterial Defense Against Antibiotic Lethality” Science 305: 1629-1631.
Bearer, J.W., et al., “SOS Response Promotes Horizontal Dissemination of Antibiotic Resistance Genes,”Nature(2004) 427:72-74.
Bhamre, S., et al., “An AerobicrecA-,umuC-Dependent Pathway of Spontaneous Base-Pair Substitution Mutagenesis inEscherichia coli,” Mutation Research(2001) vol. 473:229-247.
Boshoff, H., et al., “DnaE2 Polymerase Contributes to In Vivo Survival and the Emergence of Drug Resistance in Mycobacterium Tuberculosis,”Cell(2003) 113:183-193.
Cordell, S., et al., “Crystal Structure of the SOS Cell Division Inhibitor SulA and in Complex with FtsZ,”PNAS(2003) 100(13): 7889-7894.
Frank, E.G., et al., “Regulation of SOS Mutagenesis by Proteolysis,”PNAS(1996) 93: 10291-10296.
Liu, J., et al., “Antimicrobial Drug Discover Through Bacteriophage Genomics,”Nature Biotechnology, (2004) 22(2): 185-1991.
Napolitano, R., et al., “All three SOS-inducible DNA polymerase (Pol II, Pol IV and Pol V) are involved in induced mutagenesis,”EMBO J. (2000) 19:6259-6265.
Ramirez, B.E., et al., “Solutions Structure of Dinl Provides Insight into its Mode of RecA Inactivation,”Protein Science(2000) 9:2161-2169.
Riesentfeld, C., et al., “Adaptive Mutations Produce Resistance to Ciprofloxacin,”Antimicrobial Agents and Chemotherapy(1997) 41(9): 2059-2060.
Roland, K.L., et al., “Reaction of LexA Repressor with Diisoprophyl Fluorophosphate,”The Journal of Biological Chemistry(1990) 265(22): 12828-12835.
Rosenburg, S.M., “Evolving responsively: adaptive mutation,”Nat Rev Genet(2001) 2:504-515.
Voloshin, O., et al., “A Model for the Abrogation of the SOS Response by an SOS Protein: a Negatively Charged Helix in Dinl Mimics DNA in its Interaction with RecA,”Genes&Development(2001) 15(4): 415-427.
Arunan, C. (1999) “Solid-phase synthesis of hydrophobic peptides n 1,6-hexanediol diacrylate crosslinked poly-styrene resin: comparison with Merrifield resin.”Peptide and Peptide Letters, 6(6): 391-398.
Illenberger, S. (1998) “The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease.”Molecular Biology of the Cell, 9: 1495-1512.
Allen and Nicas (2003) “Mechanism of action of oritavancin and related glycopeptide antibodies.”FEMS Microbiology Reviews, 26: 511-532.
Ames et al. (1973) “An Improved Bacterial Test System for the Detection and Classification of Mutagens and Carcinogens.”Proceedings of the National Academy of Sciences, USA, 70(3): 782-786.
Mehlotra et al. (2001) “Evloution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America.”Proceedings of the National Academy of Sciences, USA, 98(22): 12689-12694.
Mehta et al. (1992) “In-Vivo Identification of Tumor Multidrug Resistance with Tritium-3-Colchicine.”Journal of Nucleic Medicine, 33: 1373-1377.
Cirz Ryan
David Nathaniel E.
Romesberg Floyd
Achaogen, Inc.
Quine Intellectual Property Law Group P.C.
Russel Jeffrey E
The Scripps Research Institute
LandOfFree
Compositions and methods to reduce mutagenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods to reduce mutagenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods to reduce mutagenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4043047